Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IB/II Study Evaluating The Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin in Combination With Rituximab (R) or Obinutuzumab (G) Plus Bendamustine (B) in Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Next Previous
Trial Profile

A Phase IB/II Study Evaluating The Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin in Combination With Rituximab (R) or Obinutuzumab (G) Plus Bendamustine (B) in Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 13 Dec 2022 Results assessing efficacy and safety (At final data cut-off October 21, 2021; safety run-in (N=6), randomized (N=40), and Ext (N=106) cohorts) of single-arm extension cohort study of GO29365 with extended follow-up of up to 5 years, including updated results from the Phase lb safety run-in, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
  • 07 Jun 2022 Results of meta-analysis of 3 randomized controlled trials (NCT01691898, NCT02257567 & NCT03274492) assessing risk of neutropenia and febrile neutropenia associated with use of polatuzumab vedotin for diffuse large B-cell lymphoma, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
  • 03 Dec 2021 Results assessing the cost-effectiveness of polatuzumab in combination with bendamustine and rituximab (BR) compared to BR in the treatment of patients with diffuse large B-cell lymphoma, in the Portuguese by deriving data from the GO29365, presented at the 24th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top